Drug Trial Radar · NCT07187765
Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
508
Actual
Start
Sep 22, 2025
Primary completion
Nov 30, 2025
Study completion Dec 1, 2025
Sponsor
- Lead sponsor
- Shiyou WeiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 23, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, single-center, double-blind, randomized controlled trial designed to evaluate the effect of oliceridine versus sufentanil on the incidence of hypoxemia in adult patients undergoing gastrointestinal endoscopy under deep sedation. The trial will compare the rates of hypoxemia (defined as SpO₂ ≤92%) between the two analgesic regimens when combined with propofol. The primary aim is to determine whether oliceridine can reduce the incidence of hypoxemia compared to sufentanil during endoscopic procedures.
Conditions
- Hypoxemia During Surgery
- Gastrointestinal Endoscopy
Interventions
OliceridineDrug
Oliceridine will be administered intravenously at a dose of 1 mg for gastroscopy or 1.5 mg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.
SufentanilDrug
Sufentanil will be administered intravenously at a dose of 5 μg for gastroscopy or 7.5 μg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Hypoxemia (SpO₂ ≤92%) During Sedation for Gastrointestinal EndoscopyTime frame: From the start of sedation to the end of the gastrointestinal endoscopic procedure (approximately 1-60 minutes)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianmen First People's Hospital
Tianmen, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.